Votucalis - Akari Therapeutics

Alternative Names: Votucalis

Latest Information Update: 14 Mar 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akari Therapeutics
Class Analgesics; Anti-inflammatories; Skin disorder therapies
Mechanism of Action Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Histamine H3 receptor antagonists; Histamine H4 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

10 Mar 2022 Pharmacodynamics data from a preclinical trial in Neuropathic pain and Pruritus released by Akari Therapeutics
29 Jun 2021 Preclinical trials in Atopic dermatitis in United Kingdom
02 Feb 2021 Preclinical trials in Neuropathic pain in United Kingdom (unspecified route) prior to February 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com